Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI6469 in metastatic colorectal cancer liver metastases
NCT02559024Phase 1Terminated
- Start
- Mar 2016
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of medi-6469 in colorectal cancer (CRC) (3 cohorts). Primary endpoints: Safety at 48 days and Immune Score at 27 days. Started Mar 2016; status: terminated.
02
Drugs
medi-6469
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02559024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559024.